Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter Inks Licensing Deal with INSERM for ValidPrime Technology

NEW YORK (GenomeWeb) – Tataa Biocenter today announced it has signed an exclusive agreement to license the French Institute for Health and Medical Research's (INSERM) ValidPrime qPCR assay correction technology.

ValidPrime is a tool used to measure and compensate for the genomic DNA background signal in qPCR-based gene expression measurements. The technology "accurately corrects all reactions in high-throughput qPCR BioMark arrays for signals derived from gDNA," Vlasta Korenkova, head of Tataa's Prague facility, said in a statement.

ValidPrime is an alternative to performing extra control measurements needed to eliminate the gDNA background noise, and "in our high-throughput measurements, we save up to 95 percent of reagent cost and data are of excellent quality," Korenkova said.

ValidPrime is also used to standardize analyses of cell-free DNA, Göteborg, Sweden-based Tataa, a genomic services firm, said.

Financial and other terms of the agreement were not disclosed.